Lymphoedema Evidence Library › Topics › Breast cancer-related lymphoedema
Breast cancer-related lymphoedema
Breast cancer-related lymphoedema (BCRL)
41 sources
Evidence in one minute
- Risk: higher with axillary dissection than sentinel biopsy, with radiotherapy and taxanes, BMI >25–30, and inactivity (ISL 2023). In 5 064 Turkish modified radical mastectomies, 19.9% developed lymphoedema (mean onset 29 months); BMI 30–34.9 OR 6.6. Low certainty (retrospective). Ay 2014
- Prevention: exercise reduces risk (meta-analysis, especially ≥5 nodes removed); post-operative physiotherapy associated with 10.4% vs 25.6% lymphoedema but confounded by adherence. Reverse lymphatic mapping and LYMPHA reduce incidence in several studies. Executive Committee of the International Society of Lymphology 2023
- Surveillance: baseline and serial bilateral measurement; TDC forearm ratio ≥1.2 proposed for pre-clinical BCRL (research threshold). Mayrovitz 2014
- Treatment: CDT; compression garments alone have the strongest trial support in early BCRL; MLD adds little to compression for volume. Executive Committee of the International Society of Lymphology 2023
- Pneumatic compression at home: an advanced trunk-and-arm device beat a simple 4-chamber pump (−118 v +6 ml excess volume, 36 completers, attrition unreported, p=0.05) — very low certainty (revised 2026-10-08), check funding. Fife 2012
- Taping: no effect on lymphoedema severity (SMD 0.04, 12 RCTs; low certainty); function, QoL and comfort gains very low certainty (AMSTAR 2 critically low; revised 2026-10-08). Yang 2024
- HBOT does not reduce chronic arm lymphoedema (randomised phase II, academic funding). Low certainty (revised 2026-10-08). Gothard 2010
- Surgery: the multicentre N-LVA RCT's primary outcome (Lymph-ICF total) was null at 6 months; only physical function differed, below the trial's own clinically important threshold; no volume difference (revised 2026-10-08). Jonis 2024 · Lee 2025
- South Africa: ~67 certified therapists (2014), <10% in the public sector; no national BCRL guideline; proposed referral pathway. Marco 2014
Update 2026-10-08 — downloaded evidence
- Burden in LMICs: pooled arm lymphoedema prevalence 27%, incidence 21%; BMI >25 OR ~2. Torgbenu 2020
- Axillary dissection vs sentinel biopsy: +13.7% lymphoedema, +24% pain (67 studies); PREVENT 3-year chronic BCRL ~4% after SNB vs ~26% after ALND; rural residence, BMI, supraclavicular RT and taxanes add risk. Che Bakri NA 2023 · Boyages 2023
- Immediate lymphatic reconstruction at ALND: 9.5% vs 32% BCRL (preliminary single-centre RCT, unblinded volume outcome; low certainty, revised 2026-10-08; the abstract's QoL, bioimpedance and garment claims were not significant). Coriddi 2023
- Prophylactic sleeves have not been shown to prevent BCRL (revised 2026-10-08): PLACE stopped at 53% of target, 30% v 41%, HR 0.69 (0.39–1.23) — inconclusive, a moderate benefit not excluded (low certainty); CALGB 70305 tested an exercise package with an activity-only sleeve, not prophylactic compression (low). PREVENT compared BIS- v tape-triggered sleeves (no untreated arm): less tape-defined chronic BCRL with BIS (low certainty, ImpediMed-designed). Ridner 2022 Bundred 2023 · Paskett 2021
- Resistance exercise is safe (moderate certainty); the pooled L-Dex −1.1 is a before-after change within exercise groups, not a benefit over control (revised 2026-10-08). Weight loss reduces both arms but not the inter-arm difference (low). Hasenoehrl 2020 · Tsai 2020 · Campbell 2019
- LVA RCT (N-LVA): primary outcome null at 6 months; garment discontinuation (43%) is self-reported and not a randomised contrast; at 2 years the QALY gain was not significant and the probability of cost-effectiveness from a health-service view was 8% at €20 000/QALY (revised 2026-10-08). Jonis 2024 · Kleeven 2026
- Stewart–Treves: biopsy new purple papules or atypical "cellulitis" in long-standing lymphoedema. da Costa Vieira RA 2019
Gaps
N-LVA, ILR, PLACE, CALGB 70305 and PREVENT trials now held. Still to come: N-LVA 2-year results and the final ILR report.
How the evidence points
| High | Mod. | Low | V. low | None | |
|---|---|---|---|---|---|
| Positive | 0 | 0 | 3 | 2 | 0 |
| Null or negative | 0 | 0 | 7 | 0 | 0 |
Sources on this page with a comparison, by the result of their primary outcome and the GRADE certainty of their main finding (Mod. = Moderate, V. low = Very low, None = not graded). Context sources are not counted. How direction is decided.
All 41 sources
Loading 41 sources…